Presentation is loading. Please wait.

Presentation is loading. Please wait.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Published byJared Mathews Modified over 5 years ago

Similar presentations

Presentation on theme: "A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma."— Presentation transcript:

1 A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. Comparing to the baseline (A), the patient experienced tumor burden increase at 1.4 months of therapy (B), meeting the criteria for progressive disease, which was confirmed on the serial CT scans (C). Subsequently, tumor regression to the baseline burden (+0%) was noted at 8.8 months of therapy (D). Mizuki Nishino et al. Clin Cancer Res 2017;23: ©2017 by American Association for Cancer Research

Download ppt "A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma."

Similar presentations

Figure 2. Series of surveillance bone scans

Figure 2. Series of surveillance bone scans
Fig. 4. 49-year-old female patient with two months of headaches and falls and a remote history of right lung lobectomy for reported benign tumor with MR.

Fig year-old female patient with two months of headaches and falls and a remote history of right lung lobectomy for reported benign tumor with MR.
Intervista a Angelo Delmonte

Intervista a Angelo Delmonte
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Stephen Ansell, MD, PhD Mayo Clinic

Stephen Ansell, MD, PhD Mayo Clinic
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Axial CT scans of the chest. a) Before treatment

Axial CT scans of the chest. a) Before treatment
Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)
Multiple (type 3) cyst-related primary lung malignancies presenting as cystic airspaces with asymmetrical or circumferential wall thickening. a, b) A 52-year-old.

Multiple (type 3) cyst-related primary lung malignancies presenting as cystic airspaces with asymmetrical or circumferential wall thickening. a, b) A 52-year-old.
Evaluation of complications.

Evaluation of complications.

Similar presentations

Ads by Google